New Hemorrhagic Cystitis Clinical Trial
Updated: Nov 9, 2020
A clinical trial for hemorrhagic cystitis testing a new experimental drug, LP-10 (intravesical tacrolimus) is open for enrollment for qualifying patients at sites in the Pittsburgh, PA and Detroit, MI areas. The trial sponsor is Lipella Pharmaceuticals.
The title of the trial is: A Multicenter, Dose-Ranging, Placebo-Controlled Trial Evaluating the Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis.
To learn more, including inclusion/exclusion criteria and contact information, see the ClinicalTrials.gov entry in the link (https://clinicaltrials.gov/ct2/show/NCT03129126). ClinicalTrials.gov Identifier: NCT03129126.
Disclaimer: This post is not a recommendation to join the trial and was made for awareness only. Please weigh all trial details and consult with a healthcare professional before enrolling in any potential clinical trial.